Document is current

Article History

Received: 3 February 2023

Accepted: 8 June 2023

First Online: 10 July 2023

Declarations

:

: The study was reviewed and approved by the Ethical Board of the Radboud University Medical Center (file number: 2019–5618). All participants were informed about the study’s aim and the data protection measures and were asked to provider their written informed consent prior to data collection.

: Not applicable.

: The authors declare that they have no competing interests.Prof. Bloem currently serves as co-Editor in Chief for the <i>Journal of Parkinson’s disease</i>. He serves on the editorial board of <i>Practical Neurology</i> and <i>Digital Biomarkers</i>; has received honoraria from serving on the scientific advisory board for Abbvie, Biogen and UCB; has received fees for speaking at conferences from AbbVie, Zambon, Roche, GE Healthcare and Bial; and has received research support from the Netherlands Organization for Scientific Research, the Michael J Fox Foundation, UCB, Not Impossible, the Hersenstichting Nederland, the Parkinson’s Foundation, Verily Life Sciences, Horizon 2020 and the Parkinson Vereniging (all paid to the institute).YBS is a recipient of a Radboud Excellence award. He has received research support from the UK Medical Research Council, Wellcome Trust, NIHR, Parkinson’s UK, Versus Arthritis, Gatsby Foundation and Dunhill Trust.SKLD was supported in part by a Parkinson’s Foundation-Postdoctoral Fellowship (PF-FBS-2026), a ZonMW Veni Award (09150162010183), ParkinsonNL (P2022-07 and P2021-14), Michael J Fox Foundation (MJFF-022767) and the Edmond J Safra Foundation.ADG, WMK, CJS, HW, ET, MJM and MM have no financial disclosures or potential conflicts of interest to report.